metaOBS - - Real World Evidence KB

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament	Trials	Summary Endpoints
Treament	Trials	clinical deterioration	clinical improvement	deaths	PCR-negative conversion
proton pump inhibitors (PPI)	6	OBS 2.71 [1.17; 6.30], 1 study, I2=0% statistically significant harm	-	OBS 1.76 [0.62; 4.99], 3 studies, I2=81% inconclusive result	-
alpha lipoic acid	1	-	-	0.17 [0.02; 1.44], 1 RCT, I2=0% inconclusive result	-
famotidine	1	-	-	OBS 1.64 [1.14; 2.36], 1 study, I2=0% statistically significant harm	-
5-alpha-reductase inhibitors	0	-	-	-	-
acetylcysteine	0	-	-	-	-
aviptadil	0	-	-	-	-
bevacizumab	0	-	-	-	-
bismuth	0	-	-	-	-
BLD-2660 (calpain inhibitor)	0	-	-	-	-
calcium channel blocker	0	-	-	-	-
camostat mesilate	0	-	-	-	-
continuous positive airway pressure (CPAP)	0	-	-	-	-
cytokine adsorption	0	-	-	-	-
diammonium glycyrrhizinate	0	-	-	-	-
dipyridamol	0	-	-	-	-
DPP-4 inhibitor	0	-	-	-	-
enoxaparin	0	-	-	-	-
kinin-kallikrein inhibitors	0	-	-	-	-
levamisole	0	-	-	-	-
metformin	0	-	-	-	-
natural killer (NK) cells	0	-	-	-	-
nicotin	0	-	-	-	-
nitric oxide (gas Inhalation or releasing solution)	0	-	-	-	-
ozonated autohemotherapy	0	-	-	-	-
pamrevlumab	0	-	-	-	-
povidone-iodine	0	-	-	-	-
proxalutamide	0	-	-	-	-
PUL-042 inhalation solution	0	-	-	-	-
radiotherapy	0	-	-	-	-
selinexor	0	-	-	-	-
statins	0	-	-	-	-
stem cells	0	-	-	-	-
tradipitant	0	-	-	-	-
tranilast	0	-	-	-	-
zinc	0	-	-	-	-